배너

2025.06.28 (토)

  • 구름많음동두천 27.7℃
  • 흐림강릉 29.4℃
  • 구름조금서울 29.1℃
  • 박무인천 26.9℃
  • 구름조금수원 28.8℃
  • 맑음청주 29.3℃
  • 구름조금대전 30.2℃
  • 맑음대구 32.3℃
  • 맑음전주 32.5℃
  • 연무울산 29.4℃
  • 맑음광주 31.6℃
  • 구름조금부산 26.6℃
  • 구름많음여수 27.5℃
  • 맑음제주 29.6℃
  • 구름조금천안 27.7℃
  • 구름조금경주시 32.9℃
  • 구름조금거제 28.1℃
기상청 제공

정치/경제/사회

Saean's ET-30: Electrifying Heavy-Duty Transport

Tesla Misses the Niche Market While Saean Motors Steps In
Why Tesla Semi Falls Short
Expert Endorsements for ET-30's Performance

데일리연합 (SNSJTV. 아이타임즈M) 곽중희(Kwak Joong Hee) 기자 | With the global push for ESG (Environmental, Social, and Governance) initiatives, industries like construction, waste transportation from construction sites, and mining are increasingly focusing on reducing greenhouse gas emissions.

 

Amid this shift, Saean Motors is making waves with its environmentally friendly electric trucks, presenting a competitive alternative in the specialized vehicle market.

 

 

 

As discussions around the potential repeal of the U.S. Inflation Reduction Act (IRA) gain momentum ahead of Trump’s anticipated return to the presidency, the global electric vehicle (EV) market faces significant changes. While dominated by industry giants like Tesla, there are still untapped opportunities in niche markets.

 


 

Why Tesla Semi Falls Short

 

While Tesla’s Semi truck has garnered significant attention, its design and specifications target highway logistics and long-haul freight, leaving a critical gap in the construction, waste transportation, and mining segments. Tesla has primarily focused on smooth-road freight transport, which limits its applications in off-road and heavy-duty industrial environments.

 

 

In contrast, Saean Motors has capitalized on this oversight with its ET-30, a 30-ton articulating electric truck designed specifically for challenging industrial tasks. The ET-30’s ability to handle construction waste transportation and mining logistics positions it as a practical solution where the Tesla Semi cannot compete.

 

Saean’s ET-30 not only meets the environmental demands of the ESG era but also provides practical performance capabilities that set it apart from Tesla’s highway-focused model.

 


 

Rising Demand for Environmentally Friendly Trucks Amid ESG Regulations

 

Global ESG regulations, driven by entities like the UN, have amplified the demand for electric trucks in heavy industries such as construction, waste management, and mining. These sectors are seeking sustainable solutions to meet regulatory standards, and Saean Motors has responded with its groundbreaking ET-30, a 30-ton articulating electric truck.

 

Saean’s ET-30 demonstrates impressive performance in specialized work environments such as construction waste handling and mining operations, overcoming the limitations of traditional internal combustion engine (ICE) trucks. This innovative model boasts the following specifications:

 

 

  • Dimensions: Length 8,354 mm, width 2,600 mm, height 3,328 mm.

  • Performance: Maximum power output of 410 kW (approximately 557 horsepower) and peak torque of 2,500 N·m.

  • Safety and Efficiency: A top speed of 48 km/h, load capacity of 27 tons, and an operational gradient of up to 35 degrees. It also features a 6.7-meter turning radius, ensuring maneuverability in confined spaces.

     

Expert Endorsements for ET-30's Performance

 

Professor Kim Pil-Soo of Daelim University’s Automotive Engineering Department highlighted the ET-30's exceptional value, stating, “ET-30 offers superior price-to-performance ratios and provides battery capacity and power output specifications that meet the demands of heavy trucks.” He further noted Saean’s strong position in terms of battery efficiency and output for large trucks.

 


 

A Long-Term Growth Prospect for Electric Trucks

 

As ESG-related regulations continue to tighten, the demand for electric trucks in industries like construction, waste transportation, and mining is expected to rise significantly. Beyond environmental benefits, electric trucks offer reduced noise and vibration, improved working conditions, and enhanced workforce attraction, driving positive changes in these industries.

 

Saean Motors is leveraging this momentum to expand into major global markets, including Japan, Saudi Arabia, and the United States. The company has relocated its headquarters to Las Vegas, solidifying its commitment to global expansion.

 

 

Tailored Solutions for International Markets

 

In Japan, Saean is collaborating with leading construction firms to showcase the capabilities of the ET-30. By developing customized models tailored to local needs, the company has successfully built trust and demonstrated its adaptability in meeting market demands.

 

Professor Kim emphasized the potential of the specialized truck market, stating, “The specialized truck segment holds immense potential in the global market, and Saean is carving out a new domain with its innovative technology. Key success factors include technological differentiation, competitive pricing, and the ability to meet the high torque, range, and cost-efficiency requirements of specialized and heavy-duty trucks.”

 


 

A Promising Future for Saean and the ET-30

 

With the growing emphasis on ESG standards, Saean Motors' ET-30 is well-positioned to dominate the electric truck market. Its robust performance, tailored solutions, and forward-thinking strategy are expected to solidify its foothold in the industry, setting new standards for sustainable specialized vehicles globally.


배너
배너



배너
배너

배너

SNS TV

더보기

가장 많이 본 뉴스


배너

포토뉴스

더보기

지난해 의약품 생산 32조 원 돌파…3년 만에 무역수지 흑자

데일리연합 (SNSJTV. 타임즈M) 김대영 기자 | 지난해 국내 의약품 생산 실적이 32조 원을 넘어서며 역대 최대치를 기록했다. 수출도 3년 만에 수입을 앞지르며 무역수지가 흑자로 전환됐다. 식품의약품안전처가 27일 발표한 '2024년 의약품 및 의약외품 생산·수출입 실적'에서 지난해 의약품 생산이 총 32조 8629억 원으로 전년보다 7.3% 증가했다고 밝혔다. 이는 1998년 통계 집계 이래 최대 규모다. 의약품 수출은 12조 6749억 원으로 28.2% 증가했으며, 수입액 11조 5085억 원을 상회했다. 이에 무역수지는 1조 1664억 원 흑자를 기록해 3년 만에 적자 구조를 벗어났다. 의약품 생산 증가를 이끈 것은 바이오의약품 분야였다. 바이오의약품 생산은 전년 대비 26.4% 증가한 6조 3,125억 원으로 집계됐다. 이 중 유전자재조합의약품이 3조 6687억 원으로 전체 바이오 생산의 58.1%를 차지하며 42.7%의 높은 증가율을 보였다. 셀트리온은 램시마주, 램시마펜주, 유플라이마원액 등 바이오의약품의 생산이 확대되면서 전년보다 62.5% 증가한 2조 5267억 원의 생산실적을 기록했다. 바이오의약품 수출은 32억 달러(약 4조 4,000